DGAP-News: HAEMATO AG
/ Key word(s): AGM/EGM
27.05.2020 / 08:42
The issuer is solely responsible for the content of this announcement.
HAEMATO AG Corporate News:
Due to the current uncertainties around the COVID-19 pandemic the Executive Board and the Supervisory Board of HAEMATO AG, Berlin (ISIN: DE0006190705), have decided to postpone the Annual General Meeting originally scheduled on July 8, 2020 to a later date this year. We consider the health of our shareholders, staff members and relevant service providers to be of the utmost priority.
The new date of the Annual General Meeting will be disclosed in due course at a later time.
As one of the leading providers of specialty pharmaceuticals, the HAEMATO Group benefits from competition in the primary healthcare market. The specialization in medicines for the treatment of chronic diseases and for individual therapies leads us to expect a potential for growth in the future due to demographic development.
HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing markets of high-priced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases.
HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures on the HAEMATO AG share:
27.05.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 (0)30 897 30 86 70|
|Fax:||+49 (0)30 897 30 86 79|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange|
|EQS News ID:||1056103|
|End of News||DGAP News Service|